TIGA TX
Tiga TX develops an IgA therapeutic monoclonal antibody platform to activate neutrophils for the treatment of solid tumors.
TIGA TX
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.tigatx.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Google Google Cloud Wix
Similar Organizations
Calevia
This company is a new cancer therapeutic nano technology platform for the precise targeting and thermal eradication of solid Tumors.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Venture Round - Tiga TX
Official Site Inspections
http://www.tigatx.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Tiga TX"
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Worldโs ...
Apr 7, 2025 About TigaTx TigaTx is a biotechnology company developing engineered monomeric IgA neutrophil engagers to unleash the tumour killing power of neutrophils for โฆSee details»
Tiga TX - Crunchbase Company Profile & Funding
Organization. Tiga TX . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... TigaTx received up to โฆSee details»
TigaTx 2025 Company Profile: Valuation, Investors, โฆ
TigaTx General Information Description. Developer of a proprietary platform technology designed to activate the body's neutrophils to fight cancer. The โฆSee details»
Epsilogen acquires Tiga TX - 2025-04-07 - Crunchbase
Apr 7, 2025 Acquiring Organization: Epsilogen Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer. Announced Date Apr โฆSee details»
Epsilogen buys rival cancer antibody firm TigaTx
Apr 7, 2025 Boston-based TigaTx will now operate as a subsidiary of Epsilogen, and the transaction follows financings of $35.5 million and £43.25 million (around $55 million), โฆSee details»
TigaTx - LinkedIn
Separately, TigaTx was awarded a two-year, $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the The National Institutes of ...See details»
TigaTX | Novartis Venture Fund - nvfund.com
Learn more about TigaTX, a Novartis Venture Fund portfolio company developing an IgA therapeutic monoclonal antibody platform to help treat solid tumors.See details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Worldโs ...
Apr 7, 2025 About TigaTx TigaTx is a biotechnology company developing engineered monomeric IgA neutrophil engagers to unleash the tumour killing power of neutrophils for โฆSee details»
TigaTx, Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TigaTx, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Epsilogen completes acquisition of TigaTx | The Pharmaletter
Apr 7, 2025 As a result of the combination of these two privately held companies, TigaTx becomes a wholly-owned subsidiary of Epsilogen. Financial terms of the transaction have not โฆSee details»
TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH โฆ
BOSTON, MA โ December 18, 2024 (GLOBENEWSWIRE) โ TigaTx, Inc., a biotechnology company developing a therapeutic platform technology of engineered Immunoglobulin A (IgA) โฆSee details»
Epsilogen acquires TigaTx to expand pan-isotope cancer antibody ...
Apr 8, 2025 According to GlobalDataโs Pharma Intelligence Center, Elahere is projected to make $2bn in sales in 2030. GlobalData is the parent company of Pharmaceutical Technology.. The โฆSee details»
TigaTx, Inc. (TigaTx, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅๆถ_ๆๆฐ โฆ
6 days ago TigaTx will use the ARPA-H and NIH funding to progress its lead program, TIGA-001, an IgA anti-EGFR neutrophil engager, into the clinic and generate clinical proof-of โฆSee details»
News (List) | TigaTx Corporate
Dec 18, 2024 Read about TigaTx in our latest press releases and announcements. Dec 18, 2024 TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance โฆSee details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Worldโs ...
Apr 8, 2025 Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a โฆSee details»
New isotype player enters after IGM's exit
Apr 8, 2025 Under the deal the UK's Epsilogen, whose focus is on the IgE isotype, is acquiring the US's TigaTx, which has an IgA-based project, for an undisclosed amount. Though the โฆSee details»
Tiga Tx - BioGeneration Ventures
Edward currently serves on the supervisory boards of Azafaros, Escalier BioSciences, Genase Therapeutics, Scenic Biotech, Staten Biotechnology, Synaffix and TigaTx. Read more Diede โฆSee details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Worldโs ...
LONDON & BOSTON, April 07, 2025--Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the โฆSee details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create
Apr 7, 2025 About TigaTx TigaTx is a biotechnology company developing engineered monomeric IgA neutrophil engagers to unleash the tumour killing power of neutrophils for โฆSee details»
FCOI Policy | TigaTx
Aug 26, 2024 TigaTx Inc., Financial Conflict of Interest Policy for Research Funded Under Public Health Services. ... Any ownership interest in the Company held by the Investigator since the โฆSee details»